Literature DB >> 11277732

QSAR modeling with the electrotopological state: TIBO derivatives.

J Huuskonen1.   

Abstract

Quantitative structure-activity relationships (QSAR), based on the atom level E-state indices and calculated molecular properties (log P, MR), have been developed for the affinity of a large set of TIBO derivatives against HIV-1 reverse transcriptase (HIV-1 RT) utilizing multiple linear regression techniques. A model with five descriptors, including four atom level E-state indices (carbon atoms 2, 4, 8, and 9) and calculated log P, showed good statistics both in the regression (r2 = 0.85 and s = 0.52) and leave-one-out cross-validation (q2 = 0.80 and s(PRESS) = 0.56) for the training set of 41 compounds. The statistics for the prediction of anti-HIV activity in the test set of 24 TIBO derivatives were r2 = 0.80 and s = 0.64, respectively. The model descriptors indicate the importance of lipophilic and electronic contributions toward HIV-1 RT inhibition of TIBO derivatives used in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11277732     DOI: 10.1021/ci0001435

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  3 in total

1.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

2.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection.

Authors:  Alexander Golbraikh; Alexander Tropsha
Journal:  Mol Divers       Date:  2002       Impact factor: 2.943

3.  Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs.

Authors:  Hai-Feng Chen; Bo-Tao Fan; Chen-Yang Zhao; Lan Xie; Chun-Hong Zhao; Ting Zhou; Kuo-Hsiung Lee; Graham Allaway
Journal:  J Comput Aided Mol Des       Date:  2005-04       Impact factor: 3.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.